Clinical Trials | November 14, 2025
Roche reports breakthrough phase III results for investigational multiple sclerosis drug
Fenebrutinib targets cells in the immune system known as B cells and microglia
Fenebrutinib targets cells in the immune system known as B cells and microglia
Relmada expects to initiate its Phase 3 program in the first half of 2026
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
New study presents a human-relevant stress model for assessing potential therapeutics
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
It is intended for contrast enhancement in MRI scans
A triple-action Formula for comprehensive respiratory relief
Subscribe To Our Newsletter & Stay Updated
